Exhibit 99.2

 Bringing Precision to Neurodegeneration  January 2023  ‘apri’, from the Latin word “apricum”, meaning sunlight   ‘noia’ the Greek suffix for the mind 

 Disclaimer  About This Presentation  By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: this presentation has been prepared by representatives of APRINOIA Therapeutics Inc. (“APRINOIA”) for use in presentations by APRINOIA at investor meetings for information purposes in connection with a proposed business combination (the “Business Combination”) among APRINOIA, Ross Acquisition Corp II (“ROSS”), APRINOIA Therapeutics Holdings Limited (“PubCo”), and other parties, and for no other purposes. No part of this presentation should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.   No Offer or Solicitation  This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.  No Representations or Warranties   No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither APRINOIA, ROSS, PubCo, nor any of their respective directors, officers, partners, employees, affiliates, agents, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein has not been independently verified and may be subject to updating, completion, revision and amendment and such information may change materially.  This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither APRINOIA, ROSS, PubCo, nor any of their respective directors, officers, partners, employees, affiliates, agents, advisors or representatives is under an obligation to update, revise or affirm.  Industry and Market Data   This presentation also contains information, estimates and other statistical data derived from third party sources, publicly available information, various industry publications, internal data and estimates, and assumptions made by APRINOIA based on such source’s and APRINOIA’s knowledge of the clinical-stage biotechnology industry. Information concerning APRINOIA’s industry, including APRINOIA’s general expectations and market position, is based on information obtained from various independent publicly available sources and reports, as well as management estimates. This information and any estimates provided herein involve numerous assumptions and limitations, including those related to the nature of the techniques and methodologies used in market research, and third party sources cannot guarantee the accuracy of such information. You are cautioned not to give undue weight on such estimates. Neither ROSS, APRINOIA, nor PubCo has independently verified information derived from third party sources, and makes no representation, express or implied, as to the accuracy, completeness, timeliness, reliability or availability of, such third party information. ROSS, APRINOIA and PubCo may have supplemented such information where necessary, taking into account publicly available information about other industry participants. The industry in which APRINOIA operates is subject to a high degree of uncertainty and risk. As a result, the estimates and market and industry information provided in this presentation are subject to change  Trademarks   This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and APRINOIA’s and ROSS’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copy rights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM © or ® symbols, but ROSS, APRINOIA, PubCo, and their affiliates will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. 

 Disclaimer  Cautionary Note Regarding Forward-Looking Statements   This communication contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ROSS’s, PubCo’s and/or APRINOIA’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. No representations or warranties, express or implied are given in, or in respect of, this communication. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.  These forward-looking statements and factors that may cause actual results to differ materially from current expectations include, but are not limited to: the ability of the parties to complete the Business Combination and other transactions contemplated by the Business Combination Agreement in a timely manner or at all; the risk that the Business Combination or other business combination may not be completed by ROSS’s business combination deadline and the potential failure to obtain an extension of the business combination deadline; the outcome of any legal proceedings or government or regulatory action on inquiry that may be instituted against ROSS, PubCo, APRINOIA or others following the announcement of the Business Combination and any definitive agreements with respect thereto; the inability to satisfy the conditions to the consummation of the Business Combination, including the approval of the Business Combination by the shareholders of ROSS and APRINOIA; the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement relating to the Business Combination; the ability to meet stock exchange listing standards following the consummation of the Business Combination; the effect of the announcement or pendency of the Business Combination on APRINOIA’s business relationships, operating results, current plans and operations of PubCo and APRINOIA; the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of PubCo to grow and manage growth profitably; the possibility that ROSS, PubCo and/or APRINOIA may be adversely affected by other economic, business, and/or competitive factors; estimates by ROSS, PubCo or APRINOIA of expenses and profitability; expectations with respect to future operating and financial performance and growth, including the timing of the completion of the Business Combination; plans, intentions or future operations of PubCo or APRINOIA, including relating to the finalization, completion of any studies, feasibility studies or other assessments or relating to attainment, retention or renewal of any assessments, permits, licenses or other governmental notices or approvals, or the commencement or continuation of any construction or operations of plants or facilities; APRINOIA’s and PubCo’s ability to execute on their business plans and strategy; and other risks and uncertainties described from time to time in filings with the SEC.  The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of a registration statement (as may be amended from time to time, the “Registration Statement”) to be filed by PubCo in connection with the Business Combination and other documents filed by ROSS and PubCo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. There may be additional risks that neither ROSS, PubCo nor APRINOIA presently know, or that ROSS, PubCo, and/or APRINOIA currently believe are immaterial, that could cause actual results to differ from those contained in the forward-looking statements. For these reasons, among others, investors and other interested persons are cautioned not to place undue reliance upon any forward-looking statements in this communication. None of ROSS, PubCo or APRINOIA undertakes any obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this communication, except as required by applicable law. 

 Disclaimer  Additional Information and Where to Find It  This communication relates to the proposed Business Combination between ROSS and APRINOIA. In connection with the Business Combination, PubCo intends to file a registration statement on Form F-4 with the SEC, which will include a proxy statement to ROSS shareholders and a prospectus for the registration of PubCo securities to be issued in connection with the Business Combination (as amended from time to time, the “Registration Statement”). After the Registration Statement is declared effective by the SEC, the definitive proxy statement/prospectus and other relevant documents will be mailed to the shareholders of ROSS as of the record date in the future to be established for voting on the Business Combination and will contain important information about the Business Combination and related matters. Shareholders of ROSS and other interested persons are advised to read, when available, these materials (including any amendments or supplements thereto) and any other relevant documents, because they will contain important information about ROSS, PubCo, APRINOIA and the Business Combination. Shareholders and other interested persons will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other relevant materials in connection with the Business Combination, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: Ross Acquisition Corp II, 1 Pelican Lane, Palm Beach, Florida, Attn: Wilbur L. Ross Jr., Chief Executive Officer. The information contained on, or that may be accessed through, the websites referenced in this communication in each case is not incorporated by reference into, and is not a part of, this communication.   BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF ROSS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE BUSINESS COMBINATION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.  Participants in the Solicitation  ROSS, PubCo, APRINOIA and their respective directors and executive officers may be deemed participants in the solicitation of proxies from ROSS’s shareholders in connection with the Business Combination. ROSS’s shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of ROSS in ROSS’s Form 10-K, filed with the SEC on March 31, 2022, or its most recent Form 10-Q, filed with the SEC on November 14, 2022. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to ROSS’s shareholders in connection with the Business Combination will be set forth in the proxy statement/prospectus for the Business Combination, accompanying the Registration Statement that PubCo and ROSS intend to file with the SEC. Additional information regarding the interests of participants in the solicitation of proxies in connection with the Business Combination will likewise be included in that Registration Statement. You may obtain free copies of these documents as described above. 

 Risk Factors  Risks Related to APRINOIA’s Limited Operating History, Financial Position and Need for Additional Capital  APRINOIA is a clinical-stage biotechnology company with a limited operating history and faces significant challenges and expenses as it builds its capabilities and develops its pipeline of diagnostic and therapeutic product candidates.   APRINOIA has incurred net losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future. APRINOIA has never generated any revenue from product sales and may never be profitable.   APRINOIA may need to acquire funding from time to time to complete the development and any commercialization of its product candidates, which may not be available on acceptable terms, or at all. If APRINOIA is unable to raise capital when needed, it may be forced to delay, reduce or eliminate certain of its product development programs or other operations.  Raising additional capital may cause dilution to the interests of APRINOIA’s shareholders, restrict APRINOIA’s operations or require it to relinquish rights to its technologies or product candidates.  APRINOIA is heavily dependent on the success of its lead diagnostic product candidate 18F-APN-1607 (tau PET tracer), and to a lesser extent APN-mAb005, its anti-tau antibody candidate, and degrader programs, all of which are currently or expected to be in clinical development. If APRINOIA’s clinical trials are unsuccessful, it or its licensing or collaboration partners do not obtain regulatory approval or it is unable to commercialize 18F-APN-1607, APN-mAb005, degraders, or it experiences significant delays in doing so, its business, financial condition and results of operations will be materially adversely affected.   APRINOIA operates in highly competitive and rapidly changing industries. Its competitors are evaluating diagnostic product candidates in the same indication as its lead diagnostic product candidate, 18F-APN-1607 (tau PET tracer), and could enter the market with competing products of its product candidates, which may result in a material decline in sales of affected product candidates.   Even if APRINIOA successfully obtains regulatory approvals for its product candidates, the products may not gain market acceptance, in which case APRINOIA may not be able to generate product revenues, which will materially adversely affect its business, financial condition and results of operations.  Results of preclinical studies or early phases of clinical trials may not be predictive of future study results.  Clinical trials are difficult to design and implement, involve uncertain outcomes and may not be successful.  APRINOIA depends on enrollment of patients in its clinical trials for its product candidates. If it encounters difficulties enrolling patients in its clinical trials, its clinical development activities could be delayed or otherwise adversely affected.  If serious adverse, undesirable or unacceptable side effects are identified during the development of APRINOIA’s product candidates or following approval, if any, APRINOIA may need to abandon its development of such product candidates, the commercial profile of any approved label may be limited, or APRINOIA may be subject to other significant negative consequences following marketing approval, if any.  If the clinical trials of any of APRINOIA’s product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the NMPA or other regulatory authorities, or do not otherwise produce favorable results, APRINOIA may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of its product candidates.  Preliminary, interim and topline data from APRINOIA’s clinical trials that it may announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.  APRINOIA’s preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect APRINOIA’s ability to obtain regulatory approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on APRINOIA’s business.  APRINOIA may not be successful in its efforts to extend its pipeline of product candidates, including identifying or discovering additional product candidates in the future.  Due to APRINOIA’s limited resources and access to capital, APRINOIA must prioritize development of certain product candidates. Therefore, it may fail to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success.  Changes in methods of product candidate manufacturing may result in additional costs or delays.  APRINOIA may seek to obtain orphan drug designation for certain of its product candidates such as 18F-APN-1607. Orphan drug designation may not ensure that APRINOIA will enjoy market exclusivity in a particular market, and if it fails to obtain or maintain orphan drug exclusivity for such product candidates, it may be subject to earlier competition and its potential revenue will be reduced. 

 Risk Factors  Risks Related to APRINOIA’s Business Operations  As a company currently with substantial operations outside of the United States, APRINOIA’s business is subject to economic, political, regulatory and other risks associated with international operations.  APRINOIA’s future growth and ability to compete depends on retaining its key personnel and recruiting additional qualified personnel.  APRINOIA is a fast-growing emerging company and expects to expand its development, and regulatory capabilities, and as a result, it may encounter difficulties in managing its growth, which could disrupt our operations.  The COVID-19 pandemic could adversely impact APRINOIA’s business, including its clinical trials.  APRINOIA has granted, and may continue to grant, options and other types of awards under its share incentive plans, which may result in significant share-based non-cash compensation expenses and you will incur immediate and substantial dilution.   APRINOIA’s research and development activities could be affected or delayed because of possible restrictions on animal testing.  APRINOIA’s information technology systems could face serious disruptions that could adversely affect its business.  APRINOIA is or may become subject to a variety of privacy and data security laws, policies and contractual obligations, and its failure or failure of its third-party vendors, collaborators, contractors or consultants to comply with them could harm APRINOIA’s business.  Risks Related to APRINOIA’s Relationships with Third Parties  If APRINOIA fails to maintain its relationships with its current or future business and licensing partners, its business, commercialization prospects and financial condition may be materially adversely affected.  APRINOIA may seek to form additional strategic alliances in the future with respect to its product candidates, and if it does not realize the benefits of such alliances, its business, financial condition, commercialization prospects and results of operations may be materially adversely affected.  APRINOIA relies on third parties to conduct its nonclinical and clinical studies and perform other tasks for it. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, APRINOIA may not be able to obtain regulatory approval for or commercialize our product candidates and its business could be substantially harmed.  APRINOIA currently relies on third-party suppliers for the manufacturing and supply of certain of its product candidates for use in preclinical testing and clinical trials or for commercial use in the future, which supply could become limited or interrupted or may not be of satisfactory quality and quantity. Our dependence on these third parties may also impair the advancement of our research and development programs and the development of our product candidates.   If APRINOIA engages in future acquisitions or strategic collaborations, this may increase its capital requirements, dilute its shareholders, cause it to incur debt or assume contingent liabilities and subject it to other risks.   Risks Related to the Commercialization of APRINOIA’s Product Candidates  If APRINOIA is unable to establish sales, marketing and distribution capabilities for its product candidates, or enter into sales, marketing and distribution agreements with third parties, it may not be successful in commercializing its product candidates, if and when they are approved.  The successful commercialization of its product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.  APRINOIA has never commercialized a product candidate before, which may make it difficult to evaluate the prospects for its future viability, and may lack the necessary expertise, personnel and resources to successfully commercialize its product candidates on its own or together with suitable partners.  APRINOIA’s projections regarding the size of the addressable market of its product candidates may be incorrect. In addition, the market opportunities for its diagnostic product candidates may be limited, as the relevant effective treatments for those patients may be unavailable.   APRINOIA may become exposed to costly and damaging liability claims, either when testing its product candidates in the clinic or at the commercial stage, which may limit commercialization of any product candidates that it may develop, and its product liability insurance may not cover all damages from such claims. 

 Risk Factors  Risks Related to Regulatory Approval of APRINOIA’s Product Candidates and Other Legal Compliance Matters  All material aspects of the research, development, manufacturing and commercialization of pharmaceutical products are heavily regulated, and APRINOIA may face difficulties in complying with or be unable to comply with such regulations, which could have a material adverse effect on APRINOIA’s business.  The approval processes of regulatory authorities in the United States and other applicable jurisdictions are lengthy, time-consuming and inherently unpredictable. If APRINOIA is ultimately unable to obtain regulatory approval for APRINOIA’s product candidates, APRINOIA’s business will be substantially harmed.   Even if APRINOIA completes the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent APRINOIA from obtaining approvals for the commercialization of some or all of its product candidates. As a result, it cannot predict when or if, and in which territories, it will obtain marketing approval to commercialize product candidates.  APRINOIA obtaining and maintaining regulatory approval of its product candidates in one jurisdiction does not mean that it will be successful in obtaining regulatory approval of its product candidates in other jurisdictions.  APRINOIA is currently conducting and may in the future conduct clinical trials for its product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.  Any product candidate for which APRINOIA obtains marketing approval may be subject to post-approval regulatory obligations and continued regulatory review, which may result in significant additional expense, and APRINOIA may be subject to penalties if it fails to comply with regulatory requirements or experience unanticipated problems with its diagnostic and therapeutic product candidates.   APRINOIA’s employees, independent contractors, CMOs, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.  Recently enacted and future legislation may increase the difficulty and cost for APRINOIA to obtain regulatory approval of and commercialize its diagnostic and therapeutic candidates and affect the prices it may obtain.  APRINOIA is subject to certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Any violation of such laws and regulations may subject it to criminal liability and other serious consequences.  If APRINOIA fails to comply with environmental, health and safety and social impact assessment laws and regulations, APRINOIA could become subject to fines or penalties or incur costs that could harm its business.   APRINOIA’s business operations and relationships with healthcare professionals, consultants, customers and third-party payors in the United States and elsewhere are subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose it to substantial penalties. 

 Risk Factors  Risks Related to APRINOIA’s Intellectual Property  APRINOIA may not have sufficient patent terms to effectively protect its future approved product candidates and business.  If APRINOIA is or its licensing or collaboration partners are unable to obtain, maintain, defend and enforce patent and other intellectual property rights for its technologies and product candidates, or if the scope of the patent and other intellectual property rights obtained is not sufficiently broad, APRINOIA’s competitors and other third parties could develop and commercialize technology and biologics similar or identical to APRINOIA’s, and its ability to successfully commercialize its technology and product candidates may be impaired.  APRINOIA or its licensing or collaboration partners may become subject to intellectual property-related litigation or other proceedings to protect or enforce APRINOIA’s patents or the patents of its licensors or collaborators, any of which could be expensive, time consuming, and unsuccessful, and may ultimately result in APRINOIA’s loss of ownership of intellectual property.  APRINOIA may be subject to claims challenging the inventorship of its patents and other intellectual property.  APRINOIA may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms or at all.  Any trademarks APRINOIA may obtain may be infringed or successfully challenged, resulting in harm to its business.  Changes in patent law in the United States and other applicable jurisdictions could diminish the value of patents in general, thereby impairing APRINOIA’s ability to protect its future approved product candidates.  APRINOIA may not be able to protect its intellectual property rights throughout the world.  Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.  Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and APRINOIA’s patent protection could be reduced or eliminated for non-compliance with these requirements.  Risks Related to ROSS, the Business Combination and PubCo’s Securities Following Consummation of the Business Combination  Ross Holding Company LLC (the “Sponsor”) has agreed to vote in favor of the Business Combination, regardless of how ROSS’s public shareholders vote which will increase the likelihood that ROSS will receive the requisite shareholder approval for the Business Combination even if a substantial number of public shares are voted against the Business Combination.  The Sponsor and directors and officers of ROSS have interests in the Business Combination which may be different from or in addition to (and which may conflict with) the interests of its shareholders.   The Sponsor, and ROSS’s directors, officers, advisors and their affiliates may, subject to compliance with applicable law, enter into certain transactions, including purchasing shares or warrants from public shareholders, with the purpose of decreasing the number of redemptions, which may reduce the public “float” of its securities.  There can be no assurance that the shares issued in connection with the Business Combination will be approved for listing on Nasdaq or the NYSE or that the combined company will be able to comply with the continued listing standards of Nasdaq or the NYSE, as applicable, which could limit investors’ ability to make transactions in the combined company’s securities and subject the combined company to additional trading restrictions.  The ability of ROSS shareholders to exercise redemption rights with respect to a large number of ROSS shares could deplete the ROSS trust account prior to the Business Combination and thereby diminish the amount of working capital of the combined company.  The grant and future exercise of registration rights may adversely affect the market price of PubCo ordinary shares upon consummation of the Business Combination.  The ROSS board of directors did not obtain a third-party valuation in determining whether or not to pursue the Business Combination.  The consummation of the Business Combination is subject to a number of conditions and if those conditions are not satisfied or waived, the Business Combination agreement may be terminated in accordance with its terms and the Business Combination may not be complete.  Legal proceedings in connection with the Business Combination, the outcomes of which are uncertain, could delay or prevent the completion of the Business Combination.  Each of APRINOIA and ROSS will incur significant transaction costs in connection with the Business Combination.  If ROSS is unable to complete the Business Combination with APRINOIA or another business combination by March 16, 2023 (or such later date as may be agreed by ROSS shareholders), ROSS will cease all operations except for the purpose of winding up, redeeming 100% of the outstanding public shares and, subject to the approval of its remaining shareholders and its board of directors, dissolving and liquidating.  If ROSS were deemed an “investment company” under the Investment Company Act, it may be required to institute burdensome compliance requirements and its activities may be restricted, which may make it difficult to complete the Business Combination.  If the benefits of the Business Combination do not meet the expectations of investors or securities analysts, the market price of PubCo ordinary shares may decline.  An active trading market for PubCo’s ordinary shares may not be available on a consistent basis to provide shareholders with adequate liquidity. The share price may be volatile, and shareholders could lose a significant part of their investment. 

 Sources  APRINOIA Stock Consideration  $280.0  ROSS Cash in Trust  50.0  Convertible Notes  12.5  Strategic Investor Commitment  10.0  Total  $352.5  Transaction Overview – 86% Redemptions  Illustrative Sources & Uses  APRINOIA has entered into a definitive agreement to merge with Ross Acquisition Corp. II (NYSE:ROSS), valuing the combined entity at a $319.6 million pro forma enterprise value  All-primary transaction will result in gross proceeds of $72.5 million through a combination of:  ROSS $50.0 million cash in trust(1)  $12.5 million convertible notes  $10.0 million strategic commitment from Pharma partnership  ROSS CEO will provide an equity backstop of up to $12.5 million  ROSS Sponsor has agreed to forfeit 35% of its promote and tie another 25% to a stock price-based earnout  Closing expected in 1H 2023  Transaction Summary  Pro Forma Valuation  Notes: Assumes no cash or debt on the balance sheet prior to the transaction.  (1) Assumes 86% redemptions from the $350.6M trust.  (2) Includes 28.0M consideration shares to APRINOIA, 5.0M shares to ROSS shareholders, 1.6M convertible notes shares assuming full conversion at an $8.00 conversion price, and 3.5M sponsor promote shares.  (3) Assumes 86% redemptions and excludes 2.2M sponsor promote earnout shares, 11.5M public warrants, and 5.9M sponsor warrants.  ($M, except per share amount)  Illustrative Pro Forma Ownership(3)  Share Price  $10.00  Pro Forma Shares Outstanding (M)  38.0  Pro Forma Equity Value  $380.1  (+) Debt  $0.0  (-) Cash(1)  ($60.5)  Pro Forma Enterprise Value  $319.6  ($M)  Uses  APRINOIA Stock Consideration  $280.0  Cash to Balance Sheet  60.5  Estimated Transaction Costs  12.0  Total  $352.5  (2)  (1) 

 ROSS SPAC Overview – Global Investment Experience  Stephen J. Toy  Chief Financial Officer, Co – Founder and Managing Partner of BroadPeak Global LP  Board of Director and Management experience cultivated during his time at Plascar Participações Industriais SA, WL Ross Holding Corp., Rothschild and WL Ross & Co. LLC  Wilbur L. Ross, Jr.  Restructured over $400bn of assets in various industries across more than 150 transactions, including founding $500m founding WL Ross Holding Corp in 2014  President, Chief Executive Officer and Chairman of the Board, Former US Secretary of Commerce   Nadim Qureshi  Head of M&A, Co – Founder and Managing Partner at BroadPeak Global LP  Global transaction, board, and executive leadership experience with a vast network of executives & intermediaries. As part of a private equity consortium, BroadPeak acquired DuPont’s clean technology business for $510mm  WL Ross / Nexeo Solutions  Clean Technologies  Identify  WL Ross Holding Corp. team identified Nexeo Solutions, a global materials distributor for chemicals & plastic products in North America, EMEA and Asia  Invest  WL Ross Holding Corp. announced the acquisition in 2016 for $1.65bn $1,296mm in cash and assumed net debt, up to 35mm shares of common stock ($350mm(2)) and in exchange of warrants for 2.2mm shares  Thesis  Management identified and implemented key business strategy enhancements to drive organic growth and provided guidance in navigating the public markets  Exit  In less then three years from acquisition, Univar Inc. (NYSE: UNVR) acquired Nexeo Solutions in 2019  De - SPAC  2016 

 Management Team  Scientific Advisory Board.  Ming-Kuei Jang, Ph.D.  Expert in neurodegenerative diseases, synaptic functions, and novel biomarker discovery   Founder & Chief Executive Officer   Masaomi Miyamoto, Ph.D.  Japan Site Head  Experience in CNS pharmacology, Alzheimer’s disease, sleep disorders, and drug development  Paul Tempest, Ph.D.  Head of Medicinal Chemistry  Prior history in neurodegeneration, oncology, cardiovascular diseases, and metabolic diseases  Bradford Navia, M.D., Ph.D.  Chief Medical Officer  Background in extensive clinical development, Parkinson's Disease, ALS, and Alzheimer’s Disease  Brad Hyman, MD, PhD  John B. Penney, Jr. Professor of Neurology at Harvard Medical School   SAB Member, APRINOIA  Mark Shearman, PhD  CSO, Editas Medicine  SAB Member, APRINOIA  Jeff Cummings, MD  Research Prof., UNLV  SAB Member, APRINOIA 

 OUR MISSION:   shine light on toxic targets within the brain  &  shed a ray of hope to patients  ...leveraging best in class:  science   partners  Tau PET Tracers  Tau & aSyn Degraders  Tau Antibodies  & 

 Tau Tracer in Phase 3 in China and Phase 2/3 in the US - Validated in 2,600+ patients  Discovered through a platform of small molecules that have generated exciting candidates for accurate imaging diagnostics and targeted therapeutics  Ongoing collaborations and licensing agreements   with world leading neuroscience companies  A therapeutic pipeline with diverse treatment strategies, including potential first-in-class protein degraders, modulators, and patient-tissue validated antibodies  Investment Highlights  Tau Antibody in Global Phase 1  A collection of disease-specific tau antibodies with novel properties  Meaningful clinical and platform catalysts expected within the next 18 months 

 Tau    Program Indication(s) Discovery Preclinical Phase I Phase II Phase III Market   Tx  APN-mAb005  Tau Antibody  Tauopathies  (AD, PSP, FTD)  α-Syn Degrader  Tau Degrader  2023/4E IND – U.S.  2023/4E IND – U.S.  Synucleinopathies  (PD, MSA, DLB)  Tauopathies  (AD, PSP, FTD)  Tau PET Tracer  18F-APN-1607   18F-APN-1701+   Alzheimer’s  2023E IND – U.S.  2023E NDA   China  ORPHAN   DESIGNATION  Tracers   18F-α-Synuclein   PET Tracer  Parkinson’s Disease & MSA  2023E IND – U.S.  Tracers  Dx  TDP-43 Degrader  ALS, FTD, AD  PSP  2023E Phase 1b – U.S.   2023E phase 2/3 – U.S.  2024E phase 3 – U.S.  Our future pipeline includes many diagnostic and therapeutic products*  a-syn   new   Disclosed  collaborators  *Pipeline composition and milestone timing are based on management’s expectations, subject to change 

 LEGEND  Significant Macro Momentum Across Our Domains  AD Drug Approvals   China PET Tracer Market  Degrader Deals  Tau Deals  1970’s  Today  2023-4  Industry Events*  APRINOIA Anticipated Events  Discovery of Tau protein  Steady macro growth across each of APRINOIA’s key areas  Clinical use of PET started in China  Leqembi  Aduhelm  1980’s  1990’s  2000’s  2010’s  Near-term projected milestones for APRINOIA include the 2nd ever PET approval in China, potentially the first clinical CNS degrader, and tau collaborations  ARICEPT  Exelon Patch  Namenda  Namzaric  Reminyl  AC Immune / Genetech  TauRx / Bayer  AC Immune / Genetech  *Industry events include partnerships, collaborations, licensing agreements, and M&A 

 Toxic protein aggregates, a common feature of neurodegenerative diseases  50y  60y  70y  80y  Age  Aβ aggregation   Tau aggregation   Clinical symptoms   AD  Onset of symptoms  In AD specifically, onset of tau pathology is more closely correlative with onset of clinical symptoms  Onset of Aβ pathology can precede cognitive decline by a decade   Tau aggregation is the key driver in Primary Tauopathies (e.g., PSP).  Different isoform compositions (4R-, 3R-, or 4R/3R mixed)   drive distinct pathologies in different diseases.  AD is a heterogeneous disease of which tau is only one driver.   Amyloid-ß treatment window  Tau treatment window 

 Lecanemab’s success is only the beginning…  Biomarker-based   Patient Selection  Delivery of therapeutic effects via   clinically validated warheads to targets  APRINOIA’s strategy is built upon these foundational underpinnings…  More targets will require modulation in order to address patients outside the reach of A-Beta therapies  Combination therapy will likely become standard practice  Newer modalities may broaden our ability to target certain disease drivers  Specificity to   toxic targets  In the future…  Recent AD Success has shown that:   (1) disease stage matters,   (2) Target species matters,   (3) Patient selection matters,  (4) Biomarker measurement of drug effects matters  Lecanemab learnings 

 APRINOIA’s Pipeline Addresses a Large AD Patient Population   Lecanemab  Tau Degraders  Tau Antibodies  ADDRESSABLE POPULATION:  Severe AD  Moderate AD  Mild AD  MCI   Tau+ patients  Total Addressable Alzheimer’s Disease Market (U.S.)  ~12.7 million patients by 2050  ADDRESSABLE POPULATION:  Mild AD  MCI   Amyloid-ß+ patients  Amyloid-ß Antibody  Market Determinants  Amyloid-ß +/-   Tau +/-  TDP-43 +/-  Other  Severe AD  Moderate AD  Mild AD  MCI due to AD 

 Multiple therapeutic modalities  Therapeutics  End Goal  Accurate Diagnosis  Smarter   Clinical Trials  Targeted Therapeutics  18F-PET tracers  Radioactive   Imaging Diagnostics  Enabler  If we can   see it…  …we can target it.  Established 4 platforms with different modalities:PET diagnostic tracers, small molecule modulators, degraders, and antibodies  

 We focus on neurodegenerative diseases, including Alzheimer’s Disease, Parkinson’s Disease, and rare diseases like PSP, FTD, and MSA  Expected 30 million people in China with Alzheimer’s by 2050  By 2040, AD economic burden is projected to jump over $379B annually  >10 million Alzheimer's and 2.5 million Parkinson’s patients in China  6.5 million Alzheimer's and   1 million Parkinson’s patients  Goal  >2M people worldwide suffer from rare CNS diseases like PSP, CBS, bvFTD, MSA, etc.  Our Initial   R&D Focus  139 million Alzheimer’s, Dementia, and other neurodegenerative patients worldwide by 2050 

 Market dynamics for Tau PET Tracers  CHINA  U.S.  Market Determinants (2022)  Alzheimer’s Disease patients   PSP patients   Disease modifying AD treatments  Approved PET tracers  Tau PET tracers in development  6.5M  20,000  2  17  9  10M  84,000  1  1  1  Commercial Strategy   China (Near-term)  Phase 3 expected complete in 2H23  NDA submission expected in 2024  Large pharmaceutical commercial partner – deal to include upfront, milestones, and double-digit royalties  U.S. (Medium-term)  Phase 3 expected to commence in PSP in 1H23; Phase 2 in AD ongoing  PSP trial expected to run over 15 months  (does not include ROW) 

 18F-APN-1607 in Alzheimer’s Disease (AD)   Normal  MCI  Early Alzheimer’s  Advanced Alzheimer’s  Tx  Imaging   Dx  block tau spreading  Degraders  Antibodies  Source: Internal Company data 

 Alzheimer’s  Disease  PiD-bvFTD  CBD-PNFA  CBD-bvFTD  CBD-CBS  PSP-RS  PSP-P  Neocortical Predominance  Subcortical Predominance  1. Tagai K, Ono M, Kubota M, et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. Neuron. 2021;109(1):42-58  Mixed 3R/4R Tauopathy  4R  Tauopathies  3R  Tauopathy  APN-1607 is believed to be the only PET tracer shown to reliably image 3R, 4R, or 3R/4R tauopathies  Selected publications:   bvFTD: behavioral variant frontotemporal dementia; CBS: Corticobasal syndrome; PiD: Pick’s disease; PNFA: progressive non-fluent aphasia; PSP: progressive supranuclear palsy; PSP-P: PSP-parkinsonism; RS: Richardson syndrome  Wide clinical utility is potent for both diagnostic AND small molecule drug development1 

 Best in Class - our platform improves existing tau tracers significantly  1 Jie et al. FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease. Pharmaceuticals 2021, 14, 110.  2 Shi, Y., et al. Cryo-EM structures of tau filaments from Alzheimer’s disease with PET ligand APN-1607. Acta Neuropathologica 141, 697–708 (2021).  Our PET Tracer, 18F-APN-1607  Clinically validated in >2,600 subjects; Phase 3 in China and Phase 2 in the US  Specific, with no MAO-B binding  Believed to be the only tau tracer that binds 4R tau, so it can be used in preclinical models, e.g., rTg4510 mouse model  Only tau tracer with CryoEM structure of APN-1607 bound to AD tau available, allowing further structure-based drug design2  Only tau tracer with wide utility in AD and many non-AD tauopathies, including PSP, CBS, bvFTD, PNFA, & Pick’s  Biogen and Bristol Myers-Squibb have used APN-1607 in clinical studies  18F-flortaucipir (Tauvid®, Lilly)   FDA-approved in 2020  Off-target binding (MAO-B)  Poor early detection of AD  Limited use in non-AD tauopathies  Challenges with Current PET Tracers1  18F-PI-2620 (Life Molecular Imaging)  18F-RO-948 (Roche)   Reduced off-target binding, but limitations remain due to similar chemistry as Tauvid®  18F-MK-6240 (Merck)   18F-PI-2620 (Life Molecular Imaging)  Being investigated for 4R tauopathies, however data is inconsistent  only useful in AD  useful in all tauopathies 

 We have generated protein degraders leveraging multiple binders and clearance paths  Degraders  Several binder core structures  (Proprietary)  +  20 linkers  +  4 E3 ligase   ligands  Multiple Platforms  2 autophagy   binders  E3  Proteasome Clearance  (current focus)   E2  U  Autophagy Clearance  (incubating)  degraders to clear protein aggregates in-vivo have been identified   What makes APRINOIA’s degraders different?  Proprietary clinically validated binders  Stage  Autopsy Confirmation for binders   Proprietary diagnostics for clinical enrollment  Preclinical  Preclinical*  Preclinical*  Source: Tagai K, Ono M, Kubota M, et al. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies. Neuron. 2021;109(1):42-58  Source: Internal Company Data  *Based on publicly available information 

 RAC-1298  RAC-1437  RAC-1422  a-syn Degraders  (PROTAC)  Multiple Platforms  Cellular POC in human dopaminergic neurons  Clearance via proteasome  Insoluble aSyn in brain   Veh  1h  Line61 mice, Single dose IV, 25 mg/kg  Animal POC  Cell- and brain-penetrant degraders have been discovered   Animal proof-of-concept achieved in aSyn models  Source: Internal Company data 

 Multiple Platforms  rTg4510, female mice  Single dose IV,   25 mg/kg, 24 hrs.  Tau   Degraders  (PROTAC)  Animal POC  Cell- and brain-penetrant degraders have been discovered   Female  Female  Female  Female  Animal proof-of-concept achieved in tau models  Source: Internal Company data 

 Multiple Approaches for Library Generation  Transgenic mice with human pathological tau  Phage display libraries  Spleen  Screen / Maturation / Cloning  Antibodies targeting different tau species  Phase 1a clinical stage Tau antibody detects human pathological tau  * APRINOIA leverages both Phage Display and Hybridoma Library Generation techniques  CY: cytosol; SY: synaptoneurosome; WB: western blot  mAb005  mAb010  mAb011  mAb013  mAb015  mAb032  mAb037  mAb008  mAb020  mAb025  mAb004   BmAb  APRINOIA Phase 1  Clinical Candidate   ND AD ND AD  Cytosol Synapse   AD  S1 P2  ND AD  TOTAL  A LIBRARY OF DIFFERENT ANTIBODIES  Conformational epitopes have been discovered  Pathological tau-specific antibodies have been discovered  Each Ab targets tau species with distinct subcellular distribution  mAb037 binds to more tau species than mAb005   Blood-based assays are being developed  APN-mAb005  APN-mAb037  Tau Antibodies  Multiple Platforms  A failed phase 2 clinical candidate  Backup Candidate  Source: Internal Company data 

 Novel epitopes on pathological tau species have been discovered  N1  N2  mid-region  R1  R2  R3  R4  244  274  305  336  368  45  74  103  2N4R  441  APNmAb005   APRINOIA  Material used for mapping of mAb005 and mAb037: AD brain sarkosyl-insoluble fraction  E2814  Eisai  299-303 or   362-366  JNJ63733657  Janssen  (pT212/pT217)  UCB0107  UCB/Roche  235-250  PNT001  Pinteon  Cis-pS231  AD (Phase 2)  AD (Phase 1)  BIIB076  Biogen  125-131  AD (Phase 1, discont’d)  AADvac1  Axon Neuroscience  294-305  (Vaccine)  AD (Phase 2)  AD (Phase 1)  *  *  AD (Phase 1)  Tau  Gosuranemab  Biogen  15-22  Tilavonemab  AbbVie  25-30  Semorinemab  Roche/Genentech/AC Immune  6-23  AD ( Phase 2, discont’d)  PSP (Phase 2, discont’d)  AD (Phase 2, failed)  AD ( Phase 2)  PSP (Phase 2, discont’d)  AD (Phase 2)  PSP (Phase 1)  Zagotenemab  Eli Lilly  3-7  *  AD (Phase 2, discont’d)  PRX005  Prothena/BMS  AD, PSP (Phase 1)  N-terminal epitopes   C-terminal epitopes   Lu AF87908  Lundbeck  386-408(pS396/S404)  RG7345  Roche  pS422  ACI-35  ACImmune/Janssen  pS396/S404  (Vaccine)  AD (Phase 2)  AD (Phase 1)  AD (Phase 1, discont’d)  AD (Phase 1)  MK-2214  Merck  pS413  APNmAb037   APRINOIA  *Conformation-dependent epitopes 

 Alzheimer’s  Disease  PiD-bvFTD  CBD-PNFA  CBD-bvFTD  CBD-CBS  PSP-RS  PSP-P  Mixed 3R/4R  4R  3R  Initial Focus  Second Focus Area  U.S. Prevalence  50,000 – 74,000  U.S. Prevalence  20,000  1  2  No approved therapies  Other studies have attempted to enroll patients by consensus clinical criteria, genetic subtype, or MRI  No approved therapies  Strongly linked to tau abnormalities  Several variants, such as parkinsonism, corticobasal syndrome, akinesia w/ gait freezing, and others  Form of FTD in which patients   suffer behavioral changes, like irritation or compulsion  Movement disorder which affects movement, gait, thinking, and mood   Approval is possible from a single robust efficacy trial  De-risking Tau therapeutics through Rare Disease Development 

 One study in   Early Alzheimer’s Disease*  (patients screened based on PET)  PSP trial, or  One basket trial in primary tauopathies, such as PSP, CBS, and bvFTD*  (patients screened based on PET)  Target Initiation   (Tau antibody)  1Q 2022  IND filed†  2Q 2022  first patient dosed  1H 2023  target completion  Phase 1a  Phase 1b   (Expected in 2023/24)  Phase 2/3**  † n=40, healthy volunteers; single ascending dose; 5 dosing cohorts, 8 patients / cohort  * n=40 / arm, treatment duration = 3 to 6 months, inclusion = early-stage disease with Tau PET screening; primary endpoint = safety; secondary endpoints = PET 1607 uptake, MRI, tau isoforms, autoantibodies, CSF biomarkers, etc.  ** Based on management expectations, subject to change  Potential for a single pivotal study, with only 200 to 250 patients (rare diseases)  Quicker Registration Path   (Orphan Status)  Target phase 2b (n = ~600)  Biomarkers may enable patient sample for Phase 3 to have target size in the 600-800 range  De-risking Tau therapeutics through Rare Disease Development 

 We are well positioned to be competitive, with multiple shots on goal  Pre-Clinical  Phase 1  Phase 2  Phase 3  Market  Pre-Clinical  Phase 1  Phase 2  Phase 3  Market  [18F]  APN-1701+  [18F]  GTP1**  [18F]  RO-6958948**  [18F]  PI-2620  [18F]  MK-6240   [18F]  APN-1607 (US)  [18F]  APN-1607 (CN)  [18F]  AV-1451  Tau PET   Tracers  Modulators  Degraders  Biologics  Preclinical APRINOIA candidate sourced from internal data   Source: clinicaltrials.gov, Alzforum, AdisInsight 08-2021; updated 04-2021; may not be a complete overview of all programs worldwide.  Vaccine; **For company use only  APN Tau Degraders  APN-0729  APN-mAb005  ABBV-8E12  LY-  3303560  RO-  7105705  AADvac1*  TRx0237  BIIB080  JNJ-63733657  Bepranemab(UCB-0107)  BIIB076  NPT-088  AV-1980D/R*  ACI-35*  Posiphen® (ANVS401)  ASN51  VY-TAU01  ATV: Tau  TRV 101  Tau -PROTACs  (Arvinas)  Tau -PROTACs  (C4 Tx)  Tau  BIIB092  MK-XXX  APN-mAb037+BBB  APN-mAb+CMA 

 We are well positioned to be competitive, with multiple shots on goal  Pre-Clinical  Phase 1  Phase 2  Phase 3  Market  Pre-Clinical  Phase 1  Phase 2  Phase 3  Market  AC Immune   [18F]  APN a-Syn PET Tracer  aSyn PET   Tracers  Modulators  Degraders  Biologics  Preclinical APRINOIA candidate sourced from internal data   Source: clinicaltrials.gov, ALZ Forum, Adis Insight 08-2021; may not be a complete overview of all programs worldwide.  * Vaccine  APN-aSyn- Degraders  MEDI1341  aSyn –PROTACs (Arvinas)  ANAVEX 1-41  aSyn Inhibitor (Treventis)  aSyn Inhibitor   (AC Immune)  Anle-138b  NPT 200-11  Anle-138b  Anti-aSyn antibody   (AC Immune)  aSyn antibody program   (Voyager & AbbVie)  UB-312*  Anti-aSyn antibody  (ProMIS)  ATV: aSyn   (Denali)  Lu AF82422  AFFITOPE  PD01A*  ABBV-0805  AFFITOPE  PD03A*  NPT-088  BIIB054  R07046015  (Prasinez-umab)  GZ / SAR4027671  aSyn –PROTACs  (C4 Tx/Biogen)  aSyn 

 Active Deal Environment within APRINOIA’s Domains  In the last 5 years…  Tau & aSyn deals  Protein Degradation deals  TOTAL Biobucks: > $13B  AVG Biobucks: > $1B  AVG Stage: Pre-clin / P1  TOTAL Biobucks: > $28B  AVG Biobucks: ~ $1.1B  AVG Stage: Pre-clinical  2022  Plexium  Abbvie  Discovery  $565M  2022  Amphista  Merck  Discovery  $1B  2022  Evotec  BMS  Discovery  $4.8B  2022  Proteovant  Blueprint  Discovery  $652M  2022  ABL  Sanofi  aSyn BsAb, PreC  $985M  2020  UCB  Roche  Tau mAb, Phase 1   $1.8B  2020  Prothena  Roche  aSyn mAb, PreC  $600M  2020  Sangamo  Biogen  Tau/aSyn AAV, PreC  $2.4B  Select transactions…  Select transactions… 

 COMPANY  APPROACH  LEAD ASSET STAGE  MARKET CAP*   Antibody Comps  Antibody Development: targeting pathologic forms of tau  Phase 3  $2.7B  Antibody Development: targeting oligomeric forms of beta- amyloid  Phase 1  $228M  PET Tracers, Vaccines, Antibodies and Inhibitors: targeting Tau, alpha-synuclein, and beta-amyloid  Phase 2  $183M  Degrader Comps  Small Molecule Protein Degrader Development: targeting several pathways (IL-1R/TLR, JAK/STAT, and p53) for cancers, autoimmune and inflammatory conditions  Phase 1   $1.62B  Small Molecule Protein Degrader Development: targeting various proteins involved in cancers and neurological conditions  Phase 1  $387M  Small Molecule Protein Degrader & Inhibitor Development: Targeting BTK, IKZF, and CBL-B for various cancers and autoimmune conditions  Phase 1  $516M  Protein Degradation (PROTAC):   oncology and early neurology (tau and alpha-synuclein)  Phase 2  $1.68B  Similar biotech companies have garnered significant value  * Closing market cap as of January 10, 2023 

 1H 24  Tau PET China P3 (AD)  1H 23  1H 25  aSyn Optimization  2H 22  2H 23  2H 24  IND Enabling  Tau PET China NDA  Tau PET China Commercial  Tau PET US Phase 2 (AD)  Phase 1a  Phase 1b  aSyn US Phase 0/1 (PD/MSA)  Phase 1a  Phase 1b (PSP)  Preclinical  Clinical  Commercial  Phase 1b (AD)  Tau PET US Phase 2/3 (PSP)  Tau Optimization  IND Enabling  Key milestones to be delivered   APN-1607   Phase 3 data,   China  Degraders  PET tracers  antibodies  Path to Value Inflection Points  Degrader   IND/FTIH  mAb005  Phase 1a Data  APN-1607   NDA (AD),   China  APN-1607   NDA (PSP), USA  Phase 1a  Based on management expectations, subject to change